Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Fig. 2

Outcomes of the AML cohort. A Relapse-free survival for the entire cohort, B overall survival for the entire cohort, C overall survival by presence of TP53 mutation or MECOM rearrangement, and D overall survival by clinical history of prior hypomethylating agent or chemotherapy exposure for antecedent hematologic malignancy and by presence of TP53 mutation or MECOM rearrangement

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us